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The association between susceptibility to disease and products of the MHC has
been one ofthe first observations signaling the involvement of MHC products in
immunerecognition(1-5). This linkage hasbecome better understood sincethe dis-
covery that Tcells recognize antigens only inassociation withmajortransplantation
antigens and that they recognize foreign antigen fragments that are noncovalently
bound tomajorhistocompatibility antigens (6-10). The pathophysiology ofthelinkage
between major histocompatibility antigens and disease is more complex, however,
and usually not readily reduced to MHC-dependent immune responsiveness, be-
cause the initiating antigens or agent are not known (11, 12).
It is interesting that many diseases thatexhibit MHC association ofsusceptibility are
immunologically mediated (1-4, 11), some examples being ankylosing spondylitis,
Reiter's disease(2-4, 13, 14), andjuvenile diabetes.Juvenile diabetes, an autoimmune
disease, has recently been shown to be linked to a particular type ofamino-acid sub-
stitutionon HLA orH-2 antigens (12). Inaddition, induction ofimmunopathological
processes, including autoimmune diseases, have often been linked to infections but
direct evidence is still scarce (15, 16). Infectious agents may directly cause disease
by cytopathic effects or indirectly by causing immune-mediated cell destruction or
inflammatory processes (17-21). MHC disease associations may rather rarely be-
come manifest for cytopathic viruses or bacteria, because MHC-regulated non- or
low responders would have been eliminated during evolution. In contrast, noncyto-
pathic infectious agents that do not cause disease directly, but rather indirectly via
induced immune responses, mayexhibitMHC-disease associationmoreoftenbecause
oftheirlowto absent evolutionary pressure (11); hepatitis Bvirus (5, 22, 23)or Mycobac-
terium leprae(24) infections mayserve asexamples ofsuch aphenomenon inhumans.
Murine model diseases have been used to better understand the pathophysiology
ofMHC-disease associations(25, 26); theyofferthe advantage thatthe complexities
present in humanexamples may be reducedby defining parameters ofboth the host
and ofthe inducing antigen or infectious agent. We have searched for evidence of
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MHC-disease associations in systemic infection ofmice with lymphocytic chorio-
meningitis virus (LCMV),' a virus that is non- or poorly cytopathic in its natural
host (17-21, 27). LCMV has been particularly well studied for its capacity to induce
a lethal T cell-mediated choriomeningitis . However, some LCMV (so called
viscerotropic) isolates injected intravenously also cause a severe hepatitis inT cell-com-
petent mice but not in T cell-deficient or CD8` T cell-depleted mice (28, 29) . This
model infection in mice is used here to show that H-2 class I-regulated antiviral
cytotoxic T cell responses directly influence the severity of disease (27, 30) . Impor-
tantly, the studies show how MHC linkage of disease susceptibility caused by one
infectious agent may vary, dependent upon which aspect of a disease is evaluated .
Materials and Methods
Mice.
￿
Mice of either sex were used at an age of8-16wk . Outbred ICR mice were obtained
from the Institut für Zuchthygiene, Tierspital, Zurich . Inbred B10.G (H-2q), B10.AKM
(H -2q), and B10.BR (H-2k) were purchased from Harlan-Olac, U.K . Ltd ., Bitester, U.K .
Virus and Infection .
￿
LCMVaggressive (LCMVAGG) andLCMVdocile (LCMVDOC)
ofknown concentration (measured in plaque-forming units [PFU]) were obtained directly
from Dr. C . Pfau (30-32), Rensselaer Polytechnical Institute, Troy, NY. Stocks were diluted
in medium containing 5%v heat-inactivated FCS. The LCMVAGG isolate is a neurotropic
strain ofLCMVUBC and LCMVDOC is a hepato-viscerotropic variant ; both LCMV viruses
had been isolated from the same 40-wk-old carrier mouse (32) . The two isolates were triple
plaque purified, then grown onMDCK cells as second passage virus ; from this stock virus
aliquots were grown by using low input multiplicity (0.01) of infection (31, 32) . TheLCMV
AGG and LCMVDOC pair of viruses are in many ways comparable with the LCMV
Armstrong and the clone 13 pair of LCMV viruses described by Ahmed et al . (33) . Mice
were infected intravenously with 6 x 102-10 5 PFU of LCMV.
Serum Sampling .
￿
Mice were anesthetized with ether; blood was obtained from the retro-
orbital venous plexus . In experiments where serum was collected at only r P time point,
mice were ether anesthetized and bled by cutting the thoracic inferior vena cava and there-
after collecting blood from the thoracic cavity. The blood was transferred to Microtainer tubes
(Becton Dickinson & Co., Mountain View, CA) and processed (28) . Serum samples were
analyzed individually or in pools of two to five donors .
Determination ofSerum Enzyme Concentrations.
￿
Asparate aminotransferase (AST EC 2.6 .1 .1),
alanin aminotransferase (ALT ; EC 2.6.1.2), and glutamate dehydrogenase(GLDH ; EC .1.4.1.3)
were determined by standard methods (28) . All reagents were purchased from Boehringer
Mannheim Biochemicals, Mannheim, FRG . A selective analyzer was used for the analyses
(model 705, Hitachi Ltd ., Nacka Works, Japan) .
Cyioloxic T Cell Assay .
￿
Activity of cytotoxic T cells was tested in 5'Cr release assays (27,
28, 30) . Target cells were established fibroblast or firbrosarcoma cell lines : L929 (H-2k), FS-9
(H-2 k) (30),AKM (KkDq), and DBA/l (Kq,Dq, a kind gift of Dr. F. Lehmann-Grube, Ham-
burg, FRG) . The test was performed in round-bottomed 96-well plates . Effector cells and
target cells (104) were each added in 100 al to give E/T cell ratios of 50:1, 13:1, and 4:1 .
They were mixed well and spun at 1,000 g for 4 min . The test duration was usually 5 h . Spon-
taneous "Cr release is indicated in the tables and figures .
Isolation of Lymphocytes from Livers .
￿
All livers were processed individually and were kept
on ice. Single cell suspensions were made by gently teasing the liver through a stainless steel
grid with a rubber-coated plastic syringe plunger. The resulting cell suspension was washed
thrice inmedium . The samples (7 ml) were underlaid with 5 ml of Ficoll-Hypaque solution
(Seromed ; Biochrom KG, Berlin, FRG) in a 15-ml glass tube . The tubes were spun at 2,500g
I Abbreviations used in this paper: ALT, alanin aminotransferase; AST, asparate aminotransferase ;
GLDH, glutamate dehydrogenase ; LCMV lymphocytic choriomeningitis virus ; LCMVAGG, LCMV
AGGRESSIVE ; LCMVDOC, LCMVDOCILE .LEIST ET AL.
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for 20 min in a Centra-7 centrifuge. Cells retrieved from the interphase were washed thrice
in medium, counted, and resuspended in the appropriate volume of medium for use in the
cytotoxic T cell assay (28).
Determination ofLCMV Titers in Livers.
￿
Livers were homogenized in glasstubes with Teflon
pestles in 4 ml of medium. Because of toxicity for the cell monolayers, low titers of virus
could not be determinedby plaque assays in liverhomogenates diluted 1 :10 and 1 :100. There-
fore, all virus titrationswere performed as follows. The frozen and thawed samples were seri-
ally diluted 10-fold in medium before 30-p.l aliquots were injected into four footpads. Footpad
swelling (34) on day 7-9 was recorded and the greatest dilution still giving a positive reaction
in at least two of four footpads was multiplied by the initial dilution factor and was taken
as the titer of ID5o of LCMV The ratio of ID5o to PFU was -10:1 for LCMVDOC and
-2:1 for LCMVAGG.
Results
LCMV-induced Immunopathology of the Liver: Dependence upon Virus Isolate and H-2.
Groups of four to five mice of three H-2 congenic B10 mouse strains were infected
intravenously with varying doses of the LCMV isolates LCMVDOC or LCMV
AGG and bled on days 7, 13, and 21 after infection (Table I). ALT and GLDH con-
centrations in serum were measured by standard methods (28) to assess liver cell
destruction; both enzyme values changed in parallel, therefore, only GLDH values
are reported. These values varied depending upon which isolate of LCMV was used;
LCMVDOC, a viscerotropic isolate (27-29, 32, 33) induced increased GLDH con-
TABLE I
Influence of Time after Infection with LCMV, of Virus Isolate, of Virus Dose, and of H-2
on Increases in Serum GLDH Concentrations
Serum concentration of GLDH ± SEM' at time after
Mice were infected intravenously with the indicated doses of LCMV. Determination of GLDH has been
detailed previously (28); values represent means ± SEM of groups of four to five mice.
t The LCMV isolates are described in detail previously (22, 23).
4 Values indicated represent maximally reached values measured on days 7, 13, and 21 .
Mouse strain
H-2 (KID) Virus dose Day 7
intravenous infection with:
LCMV-DOCT
Day 13 Day 21
LCMV-AGGt
Days 7, 13, and 214
(fu U/liter
1310.13R (kkk) 6 x 105 11 ± 3 508 ± 57 83 t 49 ND
6 x 104 15 ± 14 807 ± 64 21 ± 7 420 ± 12
6 x 103 11 ± 6 1,786 ± 328 37 ± 25 426 ± 9
6 x 102 12 ± 8 809 ± 127 18 1 3 516 ± 7
None 13 ± 8
B10.AKM (kkq) 6 x 105 480 ± 73 1,763 ± 424 14 ± 11 ND
6 x 104 290 ± 54 125 ± 49 15 ± 10 <32 ± 14
6x 103 122±35 17±8 16±8 <14±6
6x 102 37±22 9± 7 12±6 <12±4
None 16 ± 9
B10.G (qqq) 6 x 105 239 ± 43 801 ± 421 28 ± 7 ND
6 x 104 257 ± 29 42 ± 35 16 ± 5 <45 ± 16
6x103 154±33 7±5 9±5 <17± 10
6x102 45± 18 8±4 14±7 <10±5
None 6 ± 5272
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centration in serum in all mouse strains tested . LCMVAGG (6 x 104 PFU), a neu-
rotropic isolate, failed to induce such changes ; greater doses were not tested because
LCMVAGG replicates only to -1/10 ofthe titer ofLCMVDOC in vitro (27-29, 32).
Virus Dose and Time Dependence ofH-2D-regulated LCMV Hepatitis.
￿
The increases
in serum GLDH concentrations varied according to the virus dose, the time after
infection, and the H-2 type of the mouse infected according to the following rules
(Table I) . On day 7, GLDH concentrations were increased in B10.AKM (Dq) and
B10.G (Dq) but not in B10.BR (D
k) mice. In B10.AKM (Dq) and B10.G (Dq) mice,
GLDH concentrations correlated with the infectious dose ofLCMVDOC ; doses
<6 x 103 failed to cause a significant rise of GLDH concentations . Although no
GLDH increases were seen in B10.BR (Dk) mice on day 7, they showed high GLDH
concentrationson day 13 . The increase was inversely related to virus dose from 6 x
105 PFU causing -508 U/liter, 6 x 104 PFU causing 807 U/liter, and 6 x 103 PFU
causing 1,786 U/liter. For both B10.AKM (Dq) and B10.G (Dq) mice, the greatest
virus doses of 6 x 105 PFU/mouse still caused the greatest GLDH concentrations
on day 13 after infection . In contrast to B10.BR (Dk) mice, lower doses ofLCMV
DOC did not cause increasedGLDH concentrations in Dq mice on day 13 . On day
21, the GLDH concentrations were at control levels, except for B10.BR (Dk) mice
injected with the highest dose of 6 x 105 PFU LCMVDOC/mouse .
Correlation ofLCMV-speck CTL Activity andH-2D-dependentLCMVHepatitis .
￿
There
existed a time-dependent correlation of CTL activity, LCMV titers in liver, and
GLDH serum concentrations in B10 mice (Table I and Fig. 1) . A small infectious
dose (i.e ., 6 x 102 PFU) ofLCMVDOC triggered a good CTL response in livers
and spleens of B10.G (Dq) mice (30) ; in Dq mice this CTL response started very
FIGURE 1 .
￿
Correlations between dose
ofLCMVDOC or time after infection
or H-2 of infected host (B10.BR,
H-2k, B10.G, H-29) and CTL induc-
tion in spleen (O), or livers (A), serum
GLDH increases, and LCMV titers in
liver. GLDH values and CTL activi-
ties were determined and lymphocytes
were isolated from spleens and livers
as detailed in reference 28 . The cyto-
toxic activity of immune cells from
BIO.G mice were tested onAKM (K k,
Dy) target cells, for those from B10.BR
mice on infected L929 (K kD k) and
AKI (KbDk) cells for 5 h at 37°C .
Spontaneous SICr release was <20%
for all targets tested . All SICr release
seen on H-2-incompatible infected
targets or on uninfected H-2-compat-
ible targets was <20% . LCMV titers
were determined as detailed in refer-
ence 17 . All values are means of four
to five individually tested mice : SEM
were <10% for cytotoxicity assays,
<0 .8 loglo for LCMV titers, and
<12% for GLDH values .M
f
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early on day 6 (not shown) and peaked around day 9 (Fig. 1). This contrasted with
the CTL response found in B10.BR (Dk) mice, which has been shown to start later
by day 8 (30) and was still lower on day 9 than in 1310.G (Dq) (Fig. 1) or B10.AKM
(Dq) mice (not shown) (30). Virus titers in livers were below detection level in 1310.G
(Dq) mice on day 9 vs. N5 loglo PFU in 1310.BR (Dk) mice. GLDH serum concen-
trations were increased in B10.BR (Dk) but remained normal in B10.G (Dq) mice.
With greater infectious doses ofLCMV (6 x 104 PFU/mouse), CTL responses were
barely detectable in B10.BR (Dk) mice on day 9, whereas in B10.G (Dq) mice, they
were well developed. LCMV titers in livers were considerably greater in B10.13R
(Dk) than in 1310.G (Dq) mice, both on day 9 and on day 14. Whereas GLDH values
were greater in B10.G(Dq) mice on day 9 than in 1310.13R (Dk) mice, they had fallen
to background levels on day 14 in MOE (Dq) mice but were still very high in 1310.BR
(Dk) mice (>1,200 U/liter). This result suggested that liver cells were destroyed later
in Dk mice than in Dq mice.
Influence of LCMV Isolate, Virus Dose, and H-2 of Infected BIO Mice on Mortality after
Intravenous Infection. The LCMV isolate, the virus dose, and the H-2D of infected
1310 mice also influenced mortality due to general wasting and fulminant heptatitis
after intravenous infection. When great doses of LCMVDOC were used to infect
mice intravenously, a significant number ofB10.G (Dq) or B10.AKM (Dq) mice died
in the various experiments, usually between day 8 and 12, rarely thereafter. Mice
did notdie ofthe classical lymphocytic choriomeningitis centralnervous diseasebut
rather of general wasting, usually accompanied by very high liver enzyme concen-
trations in serum (Table I). In contrast, B10.BR (Dk) or C5713L/10 (H-2n) mice only
rarely succumbed to infection (Table II). LCMVAGG caused no mortality, except
in a few B10.G (Dq) Mice. It is noteworthy that 1310.G (Dq) and B10.AKM (Dq) mice
were apparently more susceptible to 6 x 103 or 6 x 104 PFU than to the highest
dose tested of 6 x 105 PFU. The lowest dose of6 x 102 PFU/mouse tested caused
no mortality.
TABLE II
Influence of LCMV Isolate, Virus Dose, and H-2 of Mice on Mortality
after Intravenous Infection
Mortality'
Number of mice dead by day 12/number of mice injected intravenously .
H-2K, I, D .
Numbers in parentheses represent percent mortality.
Virus isolate Dose of virus
C57BL/10
bbbl
B10.BR
kkk
B10.AKM
kkq
B10 .G
qqq
LCMV-DOC 6 x 10' 0/6 (0)0 0/18 (0) 2/6 (35) 2/6 (35)
6 x 104 0/6 (0) 1/18 (5) 8/18 (45) 9/18 (50)
6 x 10' 0/6 (0) 0/6 (0) 4/6 (65) 3/6 (50)
6 x 102 0/6 (0) 0/6 (0) 0/6 (0) 0/6 (0)
LCMV-AGG 6 x 104 0/6 (0) 0/18 (0) 0/6 (0) 2/18 (10)
6 x 10' 0/6(0) 0/18 (0) 0/18 (0) 2/18 (10)
6 x 102 0/6 (0) 0/6 (0) 0/6 (0) 0/6 (0)274
￿
MAJOR HISTOCOMPATIBILITY COMPLEX LINKAGE WITH DISEASE
TABLE III
Summary ofthe Results and their Interpretation
LCMV-DOC
High virus dose injected (105-106 PFU)
￿
Low virus dose injected (102-103PFU)
T cell-mediated
￿
T cell-medi-
Host response
￿
hepatitis
￿
Virus
￿
Virus
￿
ated hepatitis
￿
Virus
￿
Virus
anti-LCMV-CTL
￿
Early
￿
Late
￿
clearance persistence Early Late clearance persistence
High responder D9
￿
++++
￿
+
￿
++++
￿
-
￿
-
￿
-
￿
++++
￿
-
(fulminant
hepatitis)
Low responder Dk
￿
-
￿
±
￿
±
￿
+ + +
￿
-
￿
+ + +
￿
+
￿
+ +
(± chronic
hepatitis)
Discussion
The presented experiments and the MHC-disease linkages found may be sum-
marized asfollows(Table III). Infection withanoncytopathogenic virus such isLCMV
may cause in mice (or in man, hepatitis B virus infections) various disease symp-
toms, i.e., a hepatitis as revealed by (a) increases ofliver enzymes in serum (or by
histology; not shown); (b) death; or (c) a transient or long-term virus persistence.
The type of disease depends upon virus isolate, virus dose, and the H-2 D allele
of the murine host. There are two major parameters that influence severity ofdis-
ease: immune responsiveness andvirus spread. Theearlier, and thus the more efficient,
an antiviral cytotoxic T response is generated in mice (H-2Dq high responders vs.
H-2D' low responders [28]), the quicker the virus is eliminated and the more
limited is the T cell-mediated tissue damage. The greater the virus dose that in-
itiates the infection(highdosesofLCMV) or thequickeritmay replicate andspread
(LCMVDOC replicates faster, to higher titers, and in many more cells than does
LCMVAGG [27-29, 32]) before an efficient Tcell response is generated, the more
infected host cells will subsequently be destroyed. Thus, the extent ofT cell-medi-
ated immunopathology depends upon the relative starting level and the growth ki-
netics of the virus and/or the kinetics of H-2 class I-dependent antiviral CTL re-
sponses (Table III).
Ifdisease is defined by fulminant hepatitis, i.e., early (day 7-9) increases of liver
enzyme values in serum, then D9 mice are susceptible and Dk mice are resistant.
High responder BIO.G (Dq) and B10.AKM (Dq) mice developed a kind offulminant
T cell-mediated hepatitis accompanied by other systemic immunopathological
processes leading to death in 30-70% between day 7 and 12. In contrast, low re-
sponder B10.BR (Dk) mice did not eliminate virus readily because they did not de-
velop a good CTL response; therefore, they also did not die offulminant systemic
disease. The finding that B10.BRmicedid not die later after infection(e.g., between
day 14 and 30) when the CTL response would be expected to have risen may be
explained by the phenomenon of"high dose immune paralysis" defined by Hotchin
(17) in LCMV infections (19-21, 28, 29, 33, 34). High doses ofsome LCMV strains
tend to initiate a CTL response that fades quickly; with some LCMV isolates (33),
including LCMVDOC (32), this transient CTL response fails to eliminate virus
and, therefore, causes an adult virus carrier state. This phenomenon is still unex-LEIST ET AL.
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plained but may reflect immune suppression by LCMV not only of immune re-
sponses to unrelated antigens but also to LCMV itself (17, 18). If after infection
with high doses ofLCMVDOC disease is defined byvirus persistence, the Dk mice
are susceptible and D9 mice are resistant.
The two discussed inversely related disease states, i.e., early aggressive hepatitis
vs. virus persistence, may be linked pathophysiologically as follows. Slow and low
CTL responses in Dk mice favor virus persistence and fail to cause early hepatitis;
early and excellent CTL responses in Dq mice favor efficient and early LCMV clear-
ance, but this may also causeearly and acute T cell-mediated liver cell destruction.
In contrast to disease caused by high doses ofLCMVDOC, susceptibility to dis-
ease defined by increases in liver enzyme concentrations in serum caused by low
doses of LCMVDOC is linked to Dk; Dq mice do not show disease. In this case
resistance correlates with earlyCTL induction whereas susceptibility correlates with
later and weak or transient CTL induction in 1310.13R. In parallel, resistance of Dq
mice to disease caused by low doses ofLCMVDOC correlates with rapid clearance
ofvirus from livers and everywhere else, whereas D'-linked susceptibility correlates
with slow clearance of virus.
Thesefindingshave obviousimplicationsforthe evaluationand the understanding
ofthepathophysiologyofHLA-disease association inhumans(1-4). The experimental
results described here may offer an explanation to the finding in humans that HLA
linkage ofsusceptibilityto disease caused byhepatitis B virus(5, 22, 23) varies with
the disease symptoms studied: hepatitis B surface antigen carrier status is weakly
linked to HLA-1315 (relative risks of2-5), whereas chronic active hepatitis is linked
to HLA-Al or B8, or DW3-DR3 or BW35 (relative risks vary from 2 to 5); no HLA
association has been found with acute hepatitis in one study (summarized in refer-
ence 5).
The described model infection in mice reduced the complexity ofthe parameters
influencingMHC disease associationsin humansby defininghostparameters (defined
and homozygous MHC alleles on a constant non-MHC [1310] genetic background)
and viral parameters (defined tropisms and virus doses); it thereforewas ableto show
that MHC class I-linked and time-dependent disease susceptibility maybeexplained
directly byclass I-restricted (regulated)T cell responsiveness. Thus, disease caused
by noncytopathic agents may reflect discrete balanced states between spread of an
infectious agent or antigen and the immune response causing immunopathology.
One and the same kind ofinfectious agent (e.g., human hepatitis B virus or LCMV
in mice) or antigen may cause varying diseases dominated by differing symptoms
dependent upon parasite and host parameters. The virus variant may determine
cell and organ tropism, rapidity ofreplication, and spread; the host transplantation
antigen allele determines T cell immune responsiveness, which controls virus repli-
cation and spread but also severity ofT cell-mediatedhost cell destruction, i.e., im-
munopathology.
Summary
The influence ofmajortransplantation antigens on susceptibility to T cell-medi-
ated disease caused by infection with the noncytopathic virus lymphocytic chorio-
meningitis virus (LCMV) was evaluated in B10 H-2-congenic mice. Susceptibility
to early T cell-mediated liver cell destruction (day 7-9) and early mortality (before27 6
￿
MAJOR HISTOCOMPATIBILITY COMPLEX LINKAGE WITH DISEASE
day 12) was H-2139 linked and correlated directly with early (day 6-8) and high
cytotoxic T cell activity. In contrast, susceptibility to become an LCMV carrier,
inability to rapidly clear virus, or tendency to develop late hepatitis (day 14-17) was
linked to Dk and correlated with absence of early cytotoxic T cell activity. Thus,
H-213-regulated T cell-immune responses controlling both virus spread and im-
munopathology may directly determine the type and severity of disease. The results
illustrate that susceptibility to disease caused by one virus may be linked to distinct
MHC alleles dependent upon the disease parameter studied.
Receivedfor publication 24 January 1989 and in revisedform 3 April 1989.
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